Subtype
Kidney Carcinoma
CI-CAN-00005662Explore in graph →
399 active trials17 approved drugs64 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005662Explore in graph →
Clinical trials
1,682 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (283)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00325507 | Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma | completed | Phase 2 | 25 | Oxford BioMedicaINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT00397345 | TroVax Renal Immunotherapy Survival Trial | completed | Phase 3 | 733 | Oxford BioMedicaINDUSTRY | 10 | Oct 19, 2020 | clinicaltrials |
| NCT01076010 |
| An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301). |
| completed |
| Phase 3 |
| 277 |
| AVEO Pharmaceuticals, Inc.INDUSTRY |
| 15 |
| Oct 5, 2020 |
| clinicaltrials |
| NCT00113217 | Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma | completed | Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 23, 2020 | clinicaltrials |
| NCT00749892 | Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer | completed | Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT00502307 | A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma | completed | Phase 2 | 272 | AVEO Pharmaceuticals, Inc.INDUSTRY | 3 | Sep 1, 2020 | clinicaltrials |
| NCT02375776 | Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal Mobile Health Intervention(CORA) | completed | N/A | 84 | Massachusetts General HospitalOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT01649778 | Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma(PRINCIPAL) | completed | — | 662 | Novartis PharmaceuticalsINDUSTRY | 18 | Jul 15, 2020 | clinicaltrials |
| NCT04462445 | Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb(PIPELINE) | completed | Phase 2 | 25 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 0 | Jul 10, 2020 | clinicaltrials |
| NCT00853372 | AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib | completed | Phase 2 | 85 | AmgenINDUSTRY | 0 | Jul 1, 2020 | clinicaltrials |
| NCT01773655 | Clinical and Histopathologic Characteristics of BAP1 Mutations | completed | — | 196 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT01887574 | Renal Mass Registry | completed | N/A | 141 | Mayo ClinicOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT02575222 | Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma | completed | Phase 1 | 17 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 12, 2020 | clinicaltrials |
| NCT01331135 | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors(Aflac ST0901) | completed | Phase 1 | 18 | Emory UniversityOTHER | 1 | May 29, 2020 | clinicaltrials |
| NCT02187302 | CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC) | completed | Phase 2 | 115 | NewLink Genetics CorporationINDUSTRY | 2 | May 28, 2020 | clinicaltrials |
| NCT00610012 | Tumor Registry of Advanced Renal Cell Carcinoma(RCC-Registry) | completed | — | 1,500 | iOMEDICO AGINDUSTRY | 1 | May 27, 2020 | clinicaltrials |
| NCT02223052 | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | completed | Phase 1 | 89 | CelgeneINDUSTRY | 1 | May 12, 2020 | clinicaltrials |
| NCT02923284 | NANOTECH RCC Biomarkers | completed | — | 407 | Washington University School of MedicineOTHER | 1 | May 7, 2020 | clinicaltrials |
| NCT02687139 | Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma | completed | N/A | 34 | Johns Hopkins UniversityOTHER | 1 | Apr 29, 2020 | clinicaltrials |
| NCT01510119 | Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 40 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 24, 2020 | clinicaltrials |
| NCT04350047 | Renal Cell Carcinoma and Stage IV Inferior Vena Cava Thrombus: Resection Without Thoracotomy | completed | — | 3 | Attikon HospitalOTHER | 1 | Apr 16, 2020 | clinicaltrials |
| NCT02390843 | Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors(AflacST1402) | completed | Phase 1 | 13 | Emory UniversityOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT01221506 | Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC) | completed | Early Phase 1 | 20 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 26, 2020 | clinicaltrials |
| NCT01307267 | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | completed | Phase 1 | 190 | PfizerINDUSTRY | 5 | Mar 17, 2020 | clinicaltrials |
| NCT04040712 | Fecal Microbiota Transplantation in Diarrhea Induced by Tyrosine-kinase Inhibitors | completed | N/A | 20 | Catholic University of the Sacred HeartOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT02053220 | Mechanism of Action Trial of ColoAd1(MOA) | completed | Phase 1 | 17 | Akamis BioINDUSTRY | 1 | Mar 12, 2020 | clinicaltrials |
| NCT02406521 | Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets | completed | Phase 1 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 4, 2020 | clinicaltrials |
| NCT04295174 | KIDSTAGE- Staging of Kidney Cancer Using Dual Time PET/CT and Other Biomarkers | completed | — | 70 | Odense University HospitalOTHER | 1 | Mar 4, 2020 | clinicaltrials |
| NCT02014636 | Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018) | completed | Phase 1 | 42 | Novartis PharmaceuticalsINDUSTRY | 2 | Mar 3, 2020 | clinicaltrials |
| NCT00749320 | Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC) | completed | N/A | 32 | Beth Israel Deaconess Medical CenterOTHER | 1 | Feb 26, 2020 | clinicaltrials |
| NCT02645409 | Intraoperative Folate Targeted Fluorescence in Renal Cell Carcinoma | completed | N/A | 14 | Chandru SundaramOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT02325921 | MRI in Renal Tumors | completed | — | 39 | Radboud University Medical CenterOTHER | 1 | Feb 24, 2020 | clinicaltrials |
| NCT01846520 | Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers | completed | N/A | 200 | City of Hope Medical CenterOTHER | 1 | Jan 23, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
| NCT01550367 | Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC) | completed | Phase 1 / Phase 2 | 30 | Leonard ApplemanOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT04213157 | Laparoscopic Partial Nephrectomy for cT1 Tumors | completed | — | 292 | Samsun Liv HospitalOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT01984242 | A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma(IMmotion150) | completed | Phase 2 | 305 | Hoffmann-La RocheINDUSTRY | 9 | Dec 23, 2019 | clinicaltrials |
| NCT00027820 | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | completed | Phase 1 / Phase 2 | 106 | Fred Hutchinson Cancer CenterOTHER | 3 | Dec 20, 2019 | clinicaltrials |
| NCT00304460 | Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer | completed | Phase 1 | 138 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT00106301 | Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228 | completed | Phase 2 | 2 | CelgeneINDUSTRY | 2 | Nov 18, 2019 | clinicaltrials |
| NCT01021059 | A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Nov 8, 2019 | clinicaltrials |
| NCT00923169 | Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma) | completed | Phase 1 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 29, 2019 | clinicaltrials |
| NCT01030783 | A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma(TIVO-1) | completed | Phase 3 | 517 | AVEO Pharmaceuticals, Inc.INDUSTRY | 16 | Oct 28, 2019 | clinicaltrials |
| NCT02187042 | Evaluation Of The Impact Of A Call Center In Management Of Metastatic And/Or Advanced Renal Cell Carcinoma Patients Treated With Sunitinib (Sutent) In First Line(RENACALL) | completed | — | 70 | PfizerINDUSTRY | 1 | Oct 24, 2019 | clinicaltrials |
| NCT02700568 | Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors(FavorAx) | completed | Phase 2 | 21 | Kidney Cancer Research BureauOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT02864615 | Safety and Preliminary Efficacy of SBRT in Patients With Metastatic RCC Treated With Targeted or IO Therapy | completed | N/A | 17 | Kidney Cancer Research BureauOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT03379012 | Testosterone in Metastatic Renal Cell Carcinoma Patients(FARETES) | completed | Phase 2 | 60 | Kidney Cancer Research BureauOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT00106613 | A Research Study for Patients With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 30 | CelgeneINDUSTRY | 1 | Oct 18, 2019 | clinicaltrials |
| NCT02665039 | A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function(VINGEM) | completed | Phase 2 | 62 | Dr Anders UllénOTHER | 2 | Oct 8, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Oct 19, 2020source: clinicaltrials